<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR3">
 <label>3.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zhu</surname>
    <given-names>FC</given-names>
   </name>
   <name>
    <surname>Wurie</surname>
    <given-names>AH</given-names>
   </name>
   <name>
    <surname>Hou</surname>
    <given-names>LH</given-names>
   </name>
   <name>
    <surname>Liang</surname>
    <given-names>Q</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>YH</given-names>
   </name>
   <name>
    <surname>Russell</surname>
    <given-names>JB</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial</article-title>
  <source>Lancet</source>
  <year>2017</year>
  <volume>389</volume>
  <fpage>621</fpage>
  <lpage>628</lpage>
  <pub-id pub-id-type="doi">10.1016/S0140-6736(16)32617-4</pub-id>
  <?supplied-pmid 28017399?>
  <pub-id pub-id-type="pmid">28017399</pub-id>
 </element-citation>
</ref>
